Prediction of CYP2D6-mediated polymorphic drug metabolism (sparteine type) based on in vitro investigations
- 29 March 1996
- journal article
- review article
- Published by Elsevier in Journal of Chromatography B: Biomedical Sciences and Applications
- Vol. 678 (1) , 93-103
- https://doi.org/10.1016/0378-4347(95)00234-0
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Pharmacogenetic Phenotyping and GenotypingClinical Pharmacokinetics, 1994
- The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and NomenclatureDNA and Cell Biology, 1993
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Long-term culture of functional hepatocytesToxicology in Vitro, 1990
- Expression of cytochrome P‐450 enzymes in cultured human hepatocytesEuropean Journal of Biochemistry, 1990
- Recent Developments in Hepatic Drug OxidationClinical Pharmacokinetics, 1990
- Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.Circulation, 1987
- Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.BMJ, 1982
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977